Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma

Functional interplay between secreted ligands and receptors in melanoma

(2018) Cecilia Herraiz et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

(2017) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?

(2017) Constance E. Brinckerhoff   JOURNAL OF CELLULAR PHYSIOLOGY

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

(2017) Tsukasa Shibue et al.   Nature Reviews Clinical Oncology

Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma

(2017) Paola Bendinelli et al.   Cell Death & Disease

Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation

(2016) Lucia Kucerova et al.   BMC CANCER

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016

(2016) Claus Garbe et al.   EUROPEAN JOURNAL OF CANCER

The role of HGF/c-MET signaling pathway in lymphoma

(2016) Bao Quoc Lam et al.   Journal of Hematology & Oncology

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

(2016) Paul E. Hughes et al.   MOLECULAR CANCER THERAPEUTICS

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) R. Dummer et al.   ANNALS OF ONCOLOGY

Modes of cancer cell invasion and the role of the microenvironment

(2015) Andrew G Clark et al.   CURRENT OPINION IN CELL BIOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion

(2015) Hui-Hui Cao et al.   Molecular Cancer

c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

(2015) Hyung Kwon Byeon et al.   MOLECULAR CARCINOGENESIS

Tumour exosome integrins determine organotropic metastasis

(2015) Ayuko Hoshino et al.   NATURE

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

Targeting c-Met in melanoma

(2014) Deven Etnyre et al.   CANCER BIOLOGY & THERAPY

Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC/5FC therapy in human melanoma xenograft model

(2014) L Kucerova et al.   GENE THERAPY

Met endosomal signalling: In the right place, at the right time

(2014) Rachel Barrow-McGee et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements

(2014) D. Kazandjian et al.   ONCOLOGIST

c-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell

(2014) Young Chang Lim et al.   ORAL ONCOLOGY

The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance

(2014) Christiane R. Maroun et al.   PHARMACOLOGY & THERAPEUTICS

Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice

(2013) B. Sennino et al.   CANCER RESEARCH

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

(2013) C. Basilico et al.   CLINICAL CANCER RESEARCH

Role of cMET in the Development and Progression of Colorectal Cancer

(2013) Juan Pérez-Vargas et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

(2013) O. Surriga et al.   MOLECULAR CANCER THERAPEUTICS

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Tumor metastasis: moving new biological insights into the clinic

(2013) Liling Wan et al.   NATURE MEDICINE

Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands

(2012) Seiji Yano et al.   CANCER SCIENCE

Higher Levels of c-Met Expression and Phosphorylation Identify Cell Lines With Increased Sensitivity to AMG-458, a Novel Selective c-Met Inhibitor With Radiosensitizing Effects

(2012) Bo Li et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Molecular networks that regulate cancer metastasis

(2012) Daniela Spano et al.   SEMINARS IN CANCER BIOLOGY

Cancer Invasion and the Microenvironment: Plasticity and Reciprocity

(2011) Peter Friedl et al.   CELL

Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

(2011) K. E. Torres et al.   CLINICAL CANCER RESEARCH

Association of activated c-Met with NRAS-mutated human melanomas

(2011) Chandrani Chattopadhyay et al.   INTERNATIONAL JOURNAL OF CANCER

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

(2011) Yu Kataoka et al.   INVESTIGATIONAL NEW DRUGS

Melanoma stem cells: not rare, but well done

(2011) Sasha D Girouard et al.   LABORATORY INVESTIGATION

c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype

(2011) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Metastasis: cancer cell’s escape from oxidative stress

(2010) Giovambattista Pani et al.   CANCER AND METASTASIS REVIEWS

MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor

(2010) B.-S. Pan et al.   CANCER RESEARCH

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma

(2010) I. Kenessey et al.   CURRENT CANCER DRUG TARGETS

Regulation of liver regeneration by growth factors and cytokines

(2010) Friederike Böhm et al.   EMBO Molecular Medicine

Expression of the Stem Cell Markers Nestin and CD133 on Circulating Melanoma Cells

(2010) Alberto Fusi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Mechanisms of Motility in Metastasizing Cells

(2010) Mahmut Yilmaz et al.   MOLECULAR CANCER RESEARCH

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

(2009) F. Qian et al.   CANCER RESEARCH

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

(2009) Claus Garbe et al.   EUROPEAN JOURNAL OF CANCER

The Met tyrosine kinase receptor in development and cancer

(2008) Alessandra Gentile et al.   CANCER AND METASTASIS REVIEWS

Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)

(2008) Longbin Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of cells initiating human melanomas

(2008) Tobias Schatton et al.   NATURE